Clinical Trial

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.
Protocol Amendment History 1 change
critical Completed without a posted recruiting period 2026-08-01
Trial Details
NCT Number NCT07456059
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Healthy Adult Participants
Enrollment 24 participants
Start Date 2026-03-10
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31